Samidorphan

From WikiMD's WELLNESSPEDIA

Samidorphan (also known as ALKS-33) is a drug that acts as a potent and selective antagonist for the mu-opioid receptor. It is being developed by Alkermes for the treatment of addiction and other disorders, and has reached Phase II clinical trials for binge eating disorder and major depressive disorder.

History[edit]

Samidorphan was first developed by Alkermes, a biopharmaceutical company. It was initially investigated for its potential in treating addiction and other disorders. The drug has undergone Phase II clinical trials for binge eating disorder and major depressive disorder.

Pharmacology[edit]

Samidorphan is a potent and selective antagonist for the mu-opioid receptor. This means it blocks the action of opioids at these receptors, which can help to reduce the effects of opioid addiction.

Clinical trials[edit]

Samidorphan has undergone Phase II clinical trials for the treatment of binge eating disorder and major depressive disorder. The results of these trials are not yet available.

Potential uses[edit]

The primary potential use for Samidorphan is in the treatment of addiction, particularly opioid addiction. By blocking the action of opioids at the mu-opioid receptor, Samidorphan could help to reduce the effects of opioid addiction. It is also being investigated for potential use in treating binge eating disorder and major depressive disorder.

See also[edit]


Stub icon

This WikiMD article can only be edited by registered and verified editors. You can log in or register.

  • Samidorphan
    Samidorphan

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Samidorphan&oldid=6336611"